GlassScriptPhysician profile
Mckenzie Hamacher
NPI 1962174375
$12,116.29
in general payments reported to CMS, 2019-2025
37 companies · $4,221 in 2025
The $4,221 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.16 · 2022: $1,366 · 2023: $2,809 · 2024: $3,654 · 2025: $4,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,503.41 |
| Education | $179.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,049.61 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,356.64 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,253.35 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $739.54 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $645.93 | 2022-2025 | |
| Ardelyx, INC. | $636.57 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $619.26 | 2023-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $528.46 | 2022-2023 | |
| Genzyme Corporation | $482.11 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $440.19 | 2022-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $364.48 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $326.84 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $290.14 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $207.52 | 2022-2024 | Dificid |
| Celgene Corporation | $136.93 | 2023-2024 | Zeposia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $125.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Pharmacosmos Therapeutics INC. | $85.76 | 2022-2025 | Monoferric |
| Organon LLC | $82.20 | 2023-2024 | Hadlima |
| Celltrion USA INC. | $81.57 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $80.63 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $71.14 | 2024 | |
| Qol Medical, LLC | $64.78 | 2022-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $59.46 | 2023-2024 | Rebyota |
| Fresenius Kabi USA, LLC | $54.19 | 2023 | Idacio |
| Amgen INC. | $49.65 | 2022-2023 | Avsola, Amjevita |
| Ethicon US, LLC | $37.36 | 2023 | Linx Reflux Management System |
| Sandoz INC. | $34.74 | 2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $34.56 | 2025 | Iqirvo |
| Ucb, INC. | $23.95 | 2024 | Cimzia |
| Dexcom, INC. | $22.27 | 2024 | Dexcom G6 Transmitter |
| Braintree Laboratories, INC. | $21.42 | 2023 | Sutab |
| Vertex Pharmaceuticals Incorporated | $21.34 | 2024 | |
| Medtronic, INC. | $21.23 | 2024 | Interstim |
| Jazz Pharmaceuticals INC. | $19.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.09 | 2021 | |
| Amarin Pharma, INC. | $14.78 | 2021 | |
| Genentech USA, INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Hamacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.